Search

Your search keyword '"Gutiérrez-Herrero, Sara"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Gutiérrez-Herrero, Sara" Remove constraint Author: "Gutiérrez-Herrero, Sara"
29 results on '"Gutiérrez-Herrero, Sara"'

Search Results

2. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

3. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

5. Supplementary Figure 6 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

6. Supplementary Figure 8 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

7. Supplementary Figure Legends from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

8. Supplementary Figure 5 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

9. Supplementary Figure 3 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

10. Supplementary Figure 4 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

11. Supplementary Figure 7 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

12. Supplementary Figure 2 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

13. Supplementary Figure 1 from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

14. Supplementary Methods from NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

15. Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

16. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts

17. C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation

18. C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis

19. C3G regulates megakaryocytic differentiation and pro-platelet formation in mice

20. C3G promotes angiogenesis through the regulation of the differential release of pro-/anti-angiogenic factors from thrombin-activated platelets

21. Contribution of the Rap-GEF C3G to signaling pathways in platelets

22. C3G regulates megakaryocytic differentiation

23. C3G forma complejos con Bcr-Abl y p38αMAPK en las adhesiones focales en células de leucemia mieloide crónica. Implicaciones en la regulación de la adhesión de las células leucémicas

24. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia

25. NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

26. C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity

28. C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation.

29. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Catalog

Books, media, physical & digital resources